TMO Stock Recent News

CINCINNATI & BEND, Ore.--(BUSINESS WIRE)--To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical companies, Thermo Fisher Scientific Inc. is expanding its oral solid dose (OSD) footprint with a $22-million total investment since 2021 in its Cincinnati, Ohio, and Bend, Ore. sites. Together, these expansions will enable research and development (R&D), manufacturing and testing of OSD drug formulations – doubling the Bend site.

Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.

Biognosys' Spectronaut®, the leading vendor-agnostic software for DIA proteomics, is now directly available from Thermo Fisher Scientific under a reselling agreement End users can get access to Thermo Scientific mass spectrometry systems and Biognosys' Spectronaut software via a single offer issued by Thermo Fisher Thermo Fisher will directly quote and sell Biognosys' Spectronaut software from its product catalog ZURICH and NEWTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and provider of software solutions for mass spectrometry-based proteomics data analysis, today announced the rollout of a Value-added Reselling agreement for Biognosys' Spectronaut® software with Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning.

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has received three R&D 100 Awards for innovations that aid researchers' and scientists' work in a variety of life science applications, including proteomics, bioproduction and small-molecule analysis. Notably, the Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer (MS) won gold in the Market Disruptor special recognition category as one of the most significant advancements in mass spectr.

Thermo Fisher Scientific TMO recently secured FDA's 510(k) clearance for its SeCore CDx HLA A Sequencing System for use as a companion diagnostic (CDx) alongside Adaptimmune's ADAP newly approved T-cell receptor (TCR) therapy, TECELRA (afamitresgene autoleucel). The latter is the first engineered cell therapy for a solid tumor cancer approved in the United States and the first new therapy option in more than a decade for synovial sarcoma — a rare, soft tissue cancer that most commonly impacts young adults.

Thermo Fisher Scientific is a top dividend growth stock with a complex post-pandemic situation. Recent earnings show promising growth in key segments, despite a high valuation. Strategic investments in R&D and acquisitions position TMO for continued long-term success.

Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, completion of the Olink deal, and an increase in the number of clinical trials. Financial model updates and valuation analysis suggest the stock is currently priced at fair value, making it a Hold for now.